Our proprietary assets
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
Programs
DT-9081
EP4 receptor antagonist
Solid Tumors
DT-7012
Anti-CCR8 depleting antibody
Solid Tumors
DT-9046
Biased antagonist of PAR2
Inflammation
Undisclosed GPCR targets